Literature DB >> 10577999

Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children.

D Bonnet1, D Martin, E Villain, P Jouvet, D Rabier, M Brivet, J M Saudubray.   

Abstract

BACKGROUND: The clinical manifestations of inherited disorders of fatty acid oxidation vary according to the enzymatic defect. They may present as isolated cardiomyopathy, sudden death, progressive skeletal myopathy, or hepatic failure. Arrhythmia is an unusual presenting symptom of fatty acid oxidation deficiencies. METHODS AND
RESULTS: Over a period of 25 years, 107 patients were diagnosed with an inherited fatty acid oxidation disorder. Arrhythmia was the predominant presenting symptom in 24 cases. These 24 cases included 15 ventricular tachycardias, 4 atrial tachycardias, 4 sinus node dysfunctions with episodes of atrial tachycardia, 6 atrioventricular blocks, and 4 left bundle-branch blocks in newborn infants. Conduction disorders and atrial tachycardias were observed in patients with defects of long-chain fatty acid transport across the inner mitochondrial membrane (carnitine palmitoyl transferase type II deficiency and carnitine acylcarnitine translocase deficiency) and in patients with trifunctional protein deficiency. Ventricular tachycardias were observed in patients with any type of fatty acid oxidation deficiency. Arrhythmias were absent in patients with primary carnitine carrier, carnitine palmitoyl transferase I, and medium chain acyl coenzyme A dehydrogenase deficiencies.
CONCLUSIONS: The accumulation of arrhythmogenic intermediary metabolites of fatty acids, such as long-chain acylcarnitines, may be responsible for arrhythmias. Inborn errors of fatty acid oxidation should be considered in unexplained sudden death or near-miss in infants and in infants with conduction defects or ventricular tachycardia. Diagnosis can be easily ascertained by an acylcarnitine profile from blood spots on filter paper.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577999     DOI: 10.1161/01.cir.100.22.2248

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  69 in total

Review 1.  Genetic hypoglycaemia in infancy and childhood: pathophysiology and diagnosis.

Authors:  J M Saudubray; P de Lonlay; G Touati; D Martin; M C Nassogne; P Castelnau; C Sevin; C Laborde; C Baussan; M Brivet; A Vassault; D Rabier; J P Bonnefont; P Kamoun
Journal:  J Inherit Metab Dis       Date:  2000-05       Impact factor: 4.982

Review 2.  Mitochondrial fatty acid oxidation disorders: pathophysiological studies in mouse models.

Authors:  Ute Spiekerkoetter; Philip A Wood
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

Review 3.  Heart mitochondria signaling pathways: appraisal of an emerging field.

Authors:  José Marín-García; Michael J Goldenthal
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

Review 4.  Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.

Authors:  Kenji Yamada; Takeshi Taketani
Journal:  J Hum Genet       Date:  2018-11-06       Impact factor: 3.172

Review 5.  Adult presentations of medium-chain acyl-CoA dehydrogenase deficiency (MCADD).

Authors:  T F Lang
Journal:  J Inherit Metab Dis       Date:  2009-10-11       Impact factor: 4.982

Review 6.  Mechanisms of sudden cardiac death: oxidants and metabolism.

Authors:  Kai-Chien Yang; John W Kyle; Jonathan C Makielski; Samuel C Dudley
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

Review 7.  Fatty acid oxidation disorders.

Authors:  J Lawrence Merritt; Marie Norris; Shibani Kanungo
Journal:  Ann Transl Med       Date:  2018-12

8.  Monounsaturated 14:1n-9 and 16:1n-9 fatty acids but not 18:1n-9 induce apoptosis and necrosis in murine HL-1 cardiomyocytes.

Authors:  Lars Hoffmann; Annette Seibt; Diran Herebian; Ute Spiekerkoetter
Journal:  Lipids       Date:  2013-11-27       Impact factor: 1.880

9.  Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.

Authors:  Charles R Roe; Lawrence Sweetman; Diane S Roe; France David; Henri Brunengraber
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Corresponding increase in long-chain acyl-CoA and acylcarnitine after exercise in muscle from VLCAD mice.

Authors:  Frank ter Veld; Sonja Primassin; Lars Hoffmann; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  J Lipid Res       Date:  2008-10-31       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.